GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » PE Ratio without NRI

Procaps Group (Procaps Group) PE Ratio without NRI : 86.67 (As of Jun. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-06-18), Procaps Group's share price is $2.60. Procaps Group's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.03. Therefore, Procaps Group's PE Ratio without NRI for today is 86.67.

During the past 4 years, Procaps Group's highest PE Ratio without NRI was 231.90. The lowest was 13.82. And the median was 94.67.

Procaps Group's EPS without NRI for the three months ended in Sep. 2023 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.03.

As of today (2024-06-18), Procaps Group's share price is $2.60. Procaps Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.52. Therefore, Procaps Group's PE Ratio for today is 5.00.

During the past years, Procaps Group's highest PE Ratio was 15.22. The lowest was 4.25. And the median was 7.12.

Procaps Group's EPS (Diluted) for the three months ended in Sep. 2023 was $0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.52.

Procaps Group's EPS (Basic) for the three months ended in Sep. 2023 was $0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.52.


Procaps Group PE Ratio without NRI Historical Data

The historical data trend for Procaps Group's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group PE Ratio without NRI Chart

Procaps Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22
PE Ratio without NRI
N/A N/A At Loss 350.00

Procaps Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.42 350.00 214.76 43.88 120.67

Competitive Comparison of Procaps Group's PE Ratio without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Procaps Group's PE Ratio without NRI falls into.



Procaps Group PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Procaps Group's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=2.60/0.030
=86.67

Procaps Group's Share Price of today is $2.60.
Procaps Group's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Procaps Group  (NAS:PROC) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Procaps Group PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of Procaps Group's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group (Procaps Group) Business Description

Traded in Other Exchanges
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Executives
Alexandre Weinstein Manieu director, 10 percent owner CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski director, 10 percent owner, officer: Chief Executive Officer 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski director, 10 percent owner 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust 10 percent owner OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a. 10 percent owner 3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371

Procaps Group (Procaps Group) Headlines